Medication use for ankylosing spondylitis, psoriatic arthritis, and juvenile arthritis 2016–17
Citation
AIHW
Australian Institute of Health and Welfare (2019) Medication use for ankylosing spondylitis, psoriatic arthritis, and juvenile arthritis 2016–17, AIHW, Australian Government, accessed 20 April 2024.
APA
Australian Institute of Health and Welfare. (2019). Medication use for ankylosing spondylitis, psoriatic arthritis, and juvenile arthritis 2016–17. Canberra: AIHW.
MLA
Australian Institute of Health and Welfare. Medication use for ankylosing spondylitis, psoriatic arthritis, and juvenile arthritis 2016–17. AIHW, 2019.
Vancouver
Australian Institute of Health and Welfare. Medication use for ankylosing spondylitis, psoriatic arthritis, and juvenile arthritis 2016–17. Canberra: AIHW; 2019.
Harvard
Australian Institute of Health and Welfare 2019, Medication use for ankylosing spondylitis, psoriatic arthritis, and juvenile arthritis 2016–17, AIHW, Canberra.
PDF | 666Kb
This report examines the prescription patterns for medications specific to 3 musculoskeletal conditions: ankylosing spondylitis, psoriatic arthritis and juvenile arthritis. In 2016–17, 225,000 medications specific to the treatment of either ankylosing spondylitis or psoriatic arthritis were dispensed. Analysis of de-identified unit record PBS data produced an estimate of up to 5,400 children living with juvenile arthritis in 2016–17, who were prescribed medication from the PBS.
- ISBN: 978-1-76054-612-0 (Online)
- Cat. no: PHE 262
- Pages: 36